Biostone Biologics

Biostone Biologics is a biotechnology company founded in 2017, with offices in the UK, USA, and Taiwan. The company specializes in developing and manufacturing next-generation synthetic bone graft products. Their flagship product, si-Mochi, is a synthetic bone graft putty made from multi-porous bi-phase Calcium Phosphate ceramic granules in an aqueous polymer carrier gel. si-Mochi is designed to enhance osteocyte formation and osteointegration, making it suitable for various surgical applications. It received US FDA 510(k) clearance in April 2021. Biostone Biologics is committed to quality, holding ISO 13485:2016 and MDSAP certifications. The company focuses on expanding its market presence globally, particularly in China, Europe, and the United States. In addition to si-Mochi, Biostone Co. offers a range of advanced medical devices, including synthetic bone grafts for orthopedic and spinal surgeries, dental bone graft devices, vitreous substitute materials, and innovative limb reconstruction solutions. The company serves healthcare providers and surgeons, aiming to improve patient outcomes through advanced biomaterials and medical devices.

• Employees4
• Founded2017